Active Biotech AB Interim report January - March 2015
April 23 2015 - 2:34AM
Laquinimod
- The pivotal CONCERTO clinical study is continuing according to
plan and results are expected in 2016
- Teva is holding a number of presentations of laquinimod at the
AAN Annual Meeting on April 18-25
Tasquinimod
- Results from the Phase III study 10TASQ10 showed that treatment
with tasquinimod reduced the risk of radiographic cancer
progression or death compared to placebo (rPFS, HR=0.69, CI 95%:
0.60 - 0.80) in patients with metastatic castration resistant
prostate cancer (mCRPC) who have not received chemotherapy, but did
not extend overall survival (OS, HR=1.09, CI 95%: 0.94 - 1.28)
- Further development of tasquinimod for the treatment of
prostate cancer has been discontinued. The collaboration agreement
with Ipsen will accordingly cease.
ISI
- The project is currently focusing on building up a patent
portfolio
Financial summary
MSEK |
Jan. -
Mar. |
|
Jan. - Dec. |
|
2015 |
2014 |
|
2014 |
|
Net sales |
2.9 |
2.1 |
|
10.4 |
|
|
|
|
|
|
|
Operating loss |
-57.4 |
-59.2 |
|
-228.5 |
|
Loss for the period |
-58.0 |
-60.2 |
|
-231.5 |
|
Loss per share (SEK) |
-0.64 |
-0.80 |
|
-3.02 |
|
Cash and cash equivalents |
270.5 |
298.5 |
|
328.5 |
|
For further information, please
contact:
Tomas Leanderson, President and CEO
Tel: +46 (0)46 19 20 95 Hans Kolam, CFO Tel:
+46 (0)46 19 20 44 The report is also available at
www.activebiotech.com |
Active Biotech AB(Corp.
Reg. No. 556223-9227)Box 724, SE-220 07 LundTel: +46 (0)46 19 20
00Fax: +46 (0)46 19 11 00 |
Active Biotech AB Interim report January - March 2015
http://hugin.info/1002/R/1913651/683571.pdf
HUG#1913651
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Apr 2023 to Apr 2024